Skip to main content

Urinary Succinylacetone Analysis by Gas Chromatography-Mass Spectrometry (GC-MS)

  • Protocol
Clinical Applications of Mass Spectrometry in Biomolecular Analysis

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1378))

Abstract

Succinylacetone (SA) is used for the diagnosis and monitoring of patients with tyrosinemia type I (Tyr I). SA is exclusively elevated in blood and urine of patients with Tyr I. As urinary SA concentration is much higher than blood, SA is usually tested in urine samples. Urinary SA quantitation by gas chromatography mass spectrometry (GC-MS) is described in this chapter. The urine sample in the amount of 1 μmol creatinine is used for testing. 3,4,5,6,7-13C5-succinylacetone (13C5-SA) is used as an internal standard (IS). SA and 13C5-SA are oximated and extracted from urine with organic solvents, and then derivatized to form trimethylsilane (TMS) derivatives. TMS derivatives of SA and 13C5-SA are detected and quantified by GC-MS using selective ion monitoring (SIM). The assay is linear from 0.05 to 450 mmol/mol creatinine to cover the broad range of urinary SA concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, de Baulny HO, Pintos-Morell G, Spiekerkotter U (2013) Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis 8:8

    Article  PubMed Central  PubMed  Google Scholar 

  2. Barnby E (2014) Tyrosinemia type 1: an overview of nursing care. Pediatr Nurs 40:61–68, 90

    PubMed  Google Scholar 

  3. Lindblad B, Lindstedt S, Steen G (1977) Enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A 74:4641–4645

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Santra S, Baumann U (2008) Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother 9:1229–1236

    Article  CAS  PubMed  Google Scholar 

  5. Sassa S, Kappas A (1983) Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 71:625–634

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Tuchman M, Whitley CB, Ramnaraine ML, Bowers LD, Fregien KD, Krivit W (1984) Determination of urinary succinylacetone by capillary gas chromatography. J Chromatogr Sci 22:211–215

    Article  CAS  PubMed  Google Scholar 

  7. Jakobs C, Dorland L, Wikkerink B, Kok RM, de Jong AP, Wadman SK (1988) Stable isotope dilution analysis of succinylacetone using electron capture negative ion mass fragmentography: an accurate approach to the pre- and neonatal diagnosis of hereditary tyrosinemia type I. Clin Chim Acta 171:223–231

    Article  CAS  PubMed  Google Scholar 

  8. Schierbeek H, Berger R (1989) Determination of succinylacetone and succinylacetoacetate in physiological samples as the common product 5(3)-methyl-3(5)-isoxazole propionic-acid using an isotope-dilution method and mass-spectrometry. Clin Chim Acta 184:243–250

    Article  CAS  PubMed  Google Scholar 

  9. Allard P, Grenier A, Korson MS, Zytkovicz TH (2004) Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 37:1010–1015

    Article  CAS  PubMed  Google Scholar 

  10. Rashed MS, Al-Ahaidib LY, Al-Dirbashi OY, Al Amoudi M, Al-Sayed MM, Rahbeeni Z, Al-Hassnan Z, Al-Dbaas A, Al-Owain M, Ni Luanaigh M (2005) Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia. Anal Biochem 339:310–317

    Article  CAS  PubMed  Google Scholar 

  11. Al-Dirbashi OY, Rashed MS, Jacob M, Al-Ahaideb LY, Al-Amoudi M, Rahbeeni Z, Al-Sayed MM, Al-Hassnan Z, Al-Owain M, Al-Zeidan H (2008) Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS. Biomed Chromatogr 22:1181–1185

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chunli Yu M.D., F.A.C.M.G. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Chen, H., Yu, C. (2016). Urinary Succinylacetone Analysis by Gas Chromatography-Mass Spectrometry (GC-MS). In: Garg, U. (eds) Clinical Applications of Mass Spectrometry in Biomolecular Analysis. Methods in Molecular Biology, vol 1378. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3182-8_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3182-8_30

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3181-1

  • Online ISBN: 978-1-4939-3182-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics